Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine

Hartmut Döhner, Keith W. Pratz, Courtney D. DiNardo, Andrew H. Wei, Brian A. Jonas, Vinod A. Pullarkat, Michael J. Thirman, Christian Récher, Andre C. Schuh, Sunil Babu, Xiaotong Li, Grace Ku, Zihuan Liu, Yan Sun, Jalaja Potluri, Monique Dail, Brenda Chyla, Daniel A. Pollyea

Blood (2024) 144 (21): 2211–2222.

https://doi.org/10.1182/blood.2024024944

Published: 2024

Includes: Supplemental data

Journal Articles

HIF-1α Agonist Ameliorates Acute Graft-Versus-Host Disease Via Restraining SIRT1/ PARP1 in Bone Marrow Endothelial Progenitor Cells

Xie-Na Cao, Wen-Kai Zhang, Wei Shi, Ling-Hui Xia, Li Li, Chun-Yan Sun, Yu Hu

Blood (2024) 144 (Supplement 1): 3404.

https://doi.org/10.1182/blood-2024-204456

Published: 2024

Journal Articles

HIF-1α-Dependent Autophagy Deficiency in Bone Marrow Endothelial Progenitor Cells Contributes to Acute Graft-Versus-Host Disease after Allotransplant

Wenkai Zhang, Xie-Na Cao, Wei Shi, Linghui Xia, Li Li, Chun-Yan Sun, Yu Hu

Blood (2023) 142 (Supplement 1): 4794.

https://doi.org/10.1182/blood-2023-184413

Published: 2023

Journal Articles

Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy

Blood (2022) 140 (25): 2754–2756.

https://doi.org/10.1182/blood.2022016963

Published: 2022

Includes: Supplemental data

Journal Articles

Multi-Omic Single-Cell Sequencing Reveals Genetic and Immunophenotypic Clonal Selection in Patients With FLT3-Mutated AML Treated With Gilteritinib/Venetoclax

Vanessa E. Kennedy, Cheryl Peretz, Paul Lee, Brenda Chyla, Yan Sun, Monique Dail, Jason Hill, Elaine Tran, Andrew Koh, Jessica K. Altman, Naval Daver, Mark J. Levis, James McCloskey, Alexander Perl, Catherine Smith

Blood (2022) 140 (Supplement 1): 2244–2246.

https://doi.org/10.1182/blood-2022-160304

Published: 2022

Journal Articles

ELN Risk Stratification Is Not Predictive of Outcomes for Treatment-Naïve Patients with Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine

Hartmut Döhner, Keith W. Pratz, Courtney D. DiNardo, Brian A. Jonas, Vinod A. Pullarkat, Michael J. Thirman, Christian Recher, Andre C. Schuh, Sunil Babu, Monique Dail, Grace Ku, Yan Sun, Jalaja Potluri, Brenda Chyla, Daniel A. Pollyea

Blood (2022) 140 (Supplement 1): 1441–1444.

https://doi.org/10.1182/blood-2022-169509

Published: 2022

Journal Articles

The Combination of Navitoclax and Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Mediates Responses Suggestive of Disease Modification

Francesco Passamonti, James M. Foran, Anand Tandra, Valerio De Stefano, Maria Laura Fox, Ahmad H. Mattour, Mary Frances McMullin, Andrew Charles Perkins, Gabriela Rodríguez-Macias, Hassan Sibai, Qin Qin, Yan Sun, Jalaja Potluri, Jason Harb, Jonathan How

Blood (2022) 140 (Supplement 1): 583–585.

https://doi.org/10.1182/blood-2022-157949

Published: 2022

Journal Articles

Overall Survival By Best Overall Response with Tabelecleucel in Patients with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Solid Organ or Allogeneic Hematopoietic Cell Transplant

Susan Prockop, Laurence Gamelin, Rajani Dinavahi, Yan Sun, Weizhi Zhao, Faith Galderisi, Aditi Mehta

Blood (2021) 138 (Supplement 1): 887.

https://doi.org/10.1182/blood-2021-147226

Published: 2021

Journal Articles

Molecular Responses Are Observed across Mutational Spectrum in Treatment-Naïve Higher-Risk Myelodysplastic Syndrome Patients Treated with Venetoclax Plus Azacitidine

Blood (2021) 138 (Supplement 1): 241.

https://doi.org/10.1182/blood-2021-145613

Published: 2021

Journal Articles

Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax Combined with Hypomethylating Agents

Daniel A. Pollyea, Keith W. Pratz, Andrew H. Wei, Vinod A. Pullarkat, Brian A. Jonas, Christian Recher, Sunil Babu, Andre C. Schuh, Monique Dail, Yan Sun, Jalaja Potluri, Brenda Chyla, Courtney D. DiNardo

Blood (2021) 138 (Supplement 1): 224.

https://doi.org/10.1182/blood-2021-145639

Published: 2021

Journal Articles

Human Cytomegalovirus Selectively Suppresses the Megakaryo/Thrombopoiesis of PDGFR + and αvβ3 + Megakaryocytes Via the TPO/c-Mpl Pathway after Allo-HSCT

Feng-qi Liu, Fei-er Feng, Gao-chao Zhang, Yan Su, Xue-yan Sun, Qiu-sha Huang, Qi Chen, Xiao Liu, Yun He, Xiao-lu Zhu, Hai-xia Fu, Kai-yan Liu, Xiao-hui Zhang

Blood (2020) 136 (Supplement 1): 25.

https://doi.org/10.1182/blood-2020-137115

Published: 2020

Journal Articles

Biomarker Modulation By Mivebresib (ABBV-075) +/- Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia

Gautam M. Borthakur, MD, Olatoyosi Odenike, MD, Ibrahim Aldoss, MD, David A. Rizzieri, MD, Thomas Prebet, MD PhD, Dimple A. Modi, PhD, Rujuta Joshi, Beibei Hu, Yan Sun, PhD, Johannes E. Wolff, MD, Brian A Jonas, MD PhD

Blood (2019) 134 (Supplement_1): 539.

https://doi.org/10.1182/blood-2019-126854

Published: 2019

Journal Articles

Response to Venetoclax in Combination with Low Intensity Therapy (LDAC or HMA) in Untreated Patients with Acute Myeloid Leukemia Patients with IDH, FLT3 and Other Mutations and Correlations with BCL2 Family Expression

Brenda J Chyla, PhD, Jason Harb, PhD, Christine Mantis, PhD, Jacob J Riehm, PhD, Jeremy A. Ross, PhD, Yan Sun, PhD, Xin Huang, PhD MD, Qi Jiang, PhD, Monique Dail, PhD, Franklin V. Peale, Jr., MD PhD, Jalaja Potluri, MD, John Hayslip

Blood (2019) 134 (Supplement_1): 546.

https://doi.org/10.1182/blood-2019-128373

Published: 2019

Journal Articles

T(11;14) and High BCL2 Expression Are Predictive Biomarkers of Response to Venetoclax in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Biomarker Analyses from the Phase 3 Bellini Study

Blood (2019) 134 (Supplement_1): 142.

https://doi.org/10.1182/blood-2019-126094

Published: 2019

Journal Articles

Long-Term Outcomes of Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV + PTLD) Following Solid Organ (SOT) or Allogeneic Hematopoietic Cell Transplants (HCT) Treated with Tabelecleucel on an Expanded Access Program

Susan Prockop, MD, Ran Reshef, MDMSc, Donald E. Tsai, MD PhD, Nancy Bunin, MD, Rolla Abu-Arja, MD, Kris Michael Mahadeo, MD, Wen-Kai Weng, MD PhD, Koen Van Besien, MD PhD, David Loeb, MD PhD, Sunita Dwivedy Nasta, MD, Eneida R. Nemecek, MDMBA,MSc, Minoti Hiremath, MBBS, PhD, Susan Yue, MD, Yan Sun, PhD, Willis Navarro, MD, Sarah Nikiforow, MD PhD

Blood (2019) 134 (Supplement_1): 4071.

https://doi.org/10.1182/blood-2019-124904

Published: 2019

Journal Articles

A Retrospective Analysis of Outcomes of Diffuse Large B Cell Lymphoma (DLBCL) in the Elder Patients in China

Peng Liu, Ying Han, Jianliang Yang, Xiaohui He, Changgong Zhang, Shengyu Zhou, Yan Qin, Liqiang Zhou, Song Yongwen, Ming-Zhe Han, MD, Yan Sun, Yuankai Shi, MD PhD

Blood (2018) 132 (Supplement 1): 5410.

https://doi.org/10.1182/blood-2018-99-116641

Published: 2018

Journal Articles

A Prognostic Nomogram and Survival Analysis in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients

Shiyu Jiang, Yan Qin, Peng Liu, Jiangliang Yang, Sheng Yang, Xiaohui He, Shengyu Zhou, Lin Gui, Changgong Zhang, Liqiang Zhou, Ming-Zhe Han, Yan Sun, Yuankai Shi, MD PhD

Blood (2018) 132 (Supplement 1): 2994.

https://doi.org/10.1182/blood-2018-99-116442

Published: 2018

Journal Articles

CircPVT1 Inhibit Apoptosis and Enhance Drug Resistance in Multiple Myeloma

Xiao-Yue Wan, MD, Zhang-Bo Chu, MDPhD, Yu Hu, MD PhD, Chun-Yan Sun, MD PhD, Jing Zou, PhD MD

Blood (2017) 130 (Supplement 1): 3085.

https://doi.org/10.1182/blood.V130.Suppl_1.3085.3085

Published: 2017

Journal Articles

MicroRNA-486 regulates normal erythropoiesis and enhances growth and modulates drug response in CML progenitors

Li-Sheng Wang, Ling Li, Liang Li, Su Chu, Keh-Dong Shiang, Min Li, Hui-Yan Sun, Jun Xu, Feng-Jun Xiao, Guihua Sun, John J. Rossi, YinWei Ho, Ravi Bhatia

Blood (2015) 125 (8): 1302–1313.

https://doi.org/10.1182/blood-2014-06-581926

Published: 2015

Includes: Supplemental data

Journal Articles

Brain-Derived Neurotrophic Factor Enhances Osteoclastogenesis in Multiple Myeloma via Upregulation of RANKL/OPG Ratio Both in Vitro and in a Murine Model of Myeloma Bone Disease

Li-Sha Ai, Chun-Yan Sun, Tao Guo, Ya-Dan Wang, Lu Zhang, You Qin, Lei Chen, Han Yan, Wei Zeng, Jun Fang, Yu Hu

Blood (2012) 120 (21): 568.

https://doi.org/10.1182/blood.V120.21.568.568

Published: 2012

NARROW

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine

HIF-1α Agonist Ameliorates Acute Graft-Versus-Host Disease Via Restraining SIRT1/ PARP1 in Bone Marrow Endothelial Progenitor Cells

HIF-1α-Dependent Autophagy Deficiency in Bone Marrow Endothelial Progenitor Cells Contributes to Acute Graft-Versus-Host Disease after Allotransplant

Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy

Multi-Omic Single-Cell Sequencing Reveals Genetic and Immunophenotypic Clonal Selection in Patients With FLT3-Mutated AML Treated With Gilteritinib/Venetoclax

ELN Risk Stratification Is Not Predictive of Outcomes for Treatment-Naïve Patients with Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine

The Combination of Navitoclax and Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Mediates Responses Suggestive of Disease Modification

Overall Survival By Best Overall Response with Tabelecleucel in Patients with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Solid Organ or Allogeneic Hematopoietic Cell Transplant

Molecular Responses Are Observed across Mutational Spectrum in Treatment-Naïve Higher-Risk Myelodysplastic Syndrome Patients Treated with Venetoclax Plus Azacitidine

Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax Combined with Hypomethylating Agents

Human Cytomegalovirus Selectively Suppresses the Megakaryo/Thrombopoiesis of PDGFR + and αvβ3 + Megakaryocytes Via the TPO/c-Mpl Pathway after Allo-HSCT

Biomarker Modulation By Mivebresib (ABBV-075) +/- Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia

Response to Venetoclax in Combination with Low Intensity Therapy (LDAC or HMA) in Untreated Patients with Acute Myeloid Leukemia Patients with IDH, FLT3 and Other Mutations and Correlations with BCL2 Family Expression

T(11;14) and High BCL2 Expression Are Predictive Biomarkers of Response to Venetoclax in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Biomarker Analyses from the Phase 3 Bellini Study

Long-Term Outcomes of Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV + PTLD) Following Solid Organ (SOT) or Allogeneic Hematopoietic Cell Transplants (HCT) Treated with Tabelecleucel on an Expanded Access Program

A Retrospective Analysis of Outcomes of Diffuse Large B Cell Lymphoma (DLBCL) in the Elder Patients in China

A Prognostic Nomogram and Survival Analysis in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients

CircPVT1 Inhibit Apoptosis and Enhance Drug Resistance in Multiple Myeloma

MicroRNA-486 regulates normal erythropoiesis and enhances growth and modulates drug response in CML progenitors

Brain-Derived Neurotrophic Factor Enhances Osteoclastogenesis in Multiple Myeloma via Upregulation of RANKL/OPG Ratio Both in Vitro and in a Murine Model of Myeloma Bone Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only